Safety of rFVIIa in Trauma Patients with Brain Injury
Author Information
Author(s): Yoram Kluger, Bruno Riou, Rolf Rossaint, Sandro B Rizoli, Kenneth David Boffard, Philip Iau Tsau Choong, Brian Warren, Michael Tillinger
Primary Institution: Rambam Medical Center
Hypothesis
Is rFVIIa safe for hemodynamically unstable polytrauma patients with traumatic brain injury?
Conclusion
The use of rFVIIa in hemodynamically unstable polytrauma patients with TBI did not increase the risk of mortality or adverse events.
Supporting Evidence
- 30 patients with TBI were analyzed from a larger study of 143 patients.
- No significant differences in mortality rates were found between treatment groups.
- Adverse events were similar in both rFVIIa and placebo groups.
- Patients receiving rFVIIa had more ventilator-free days compared to placebo.
- Safety profile of rFVIIa was consistent with previous studies in trauma patients.
Takeaway
This study looked at whether a medicine called rFVIIa is safe for patients with serious injuries and brain damage. It found that it doesn't seem to cause more problems.
Methodology
Post hoc analysis of a randomized, placebo-controlled trial assessing rFVIIa safety in patients with TBI and severe blunt polytrauma.
Potential Biases
Potential bias due to the post hoc nature of the analysis.
Limitations
The sample size was small and not powered to exclude safety signals.
Participant Demographics
Patients were hemodynamically unstable with a mean age of approximately 33 years, with a mix of genders.
Statistical Information
P-Value
0.19
Confidence Interval
90% CI: 22% to 71%
Statistical Significance
p=0.19
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website